Cordis' Cypher stent more cost-effective than Taxus stent, study says

By Elaine Rigoli

Tampa, Fla., July 27 - A new study suggests that Cordis Corp.'s Cypher sirolimus-eluting coronary stent is more cost-effective than the Taxus stent for treating patients at high risk of artery re-blockage.

The German study, published in the July 18 issue of the Journal of the American College of Cardiology, found that use of the Cypher stent was associated with similar in-hospital costs but significantly lower total costs at nine to 12 months compared to Taxus.

Cordis said this cost-analysis is the first study to evaluate the relationship between the clinical effectiveness and subsequent treatment costs of the Cypher stent and the Taxus stent.

Miami-based Cordis, a Johnson & Johnson company, develops interventional vascular technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.